Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire,S., Stalmans,I., Heindryckx,F., Oura,H., Tijeras-Raballand,A., Schmidt,T., Loges,S., Albrecht,I., Jonckx,B., Vinckier,S., Van,S.C., Tugues,S., Rolny,C., De,M.M., Dettori,D., Hainaud,P., Coenegrachts,L., Contreres,J.O., Van,B.T., Cuervo,H., Xiao,W.H., Le,H.C., Buysschaert,I., Kharabi,M.B., Geerts,A., Schomber,T., Bonnin,P., Lambert,V., Haustraete,J., Zacchigna,S., Rakic,J.M., Jimenez,W., Noel,A., Giacca,M., Colle,I., Foidart,J.M., Tobelem,G., Morales-Ruiz,M., Vilar,J., Maxwell,P., Vinores,S.A., Carmeliet,G., Dewerchin,M., Claesson-Welsh,L., Dupuy,E., Van,V.H., Christofori,G., Mazzone,M., Detmar,M., Collen,D., and Carmeliet,P. 2010. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190.